Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02RJY
|
||||
Former ID |
DCL001078
|
||||
Drug Name |
PHA-739358
|
||||
Synonyms |
Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Phase 2 | [1], [2] | ||
Company |
Pfizer; Nerviano
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C26H30N6O3
|
||||
InChI |
InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1
|
||||
InChIKey |
XKFTZKGMDDZMJI-HSZRJFAPSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
16541138, 23585151, 42521925, 46394298, 46513412, 57304411, 77307760, 93581266, 99373541, 99436985, 103573135, 124757005, 125163810, 126626959, 126634887, 126665979, 126730902, 131480684, 134964424, 135261930, 136340130, 136367305, 136367975, 136920406, 137147906, 137276047, 140478603, 143499036, 144115881, 152036110, 152134559, 152164575, 152186748, 152239915, 152258104, 152344035, 160646943, 162011705, 162037440, 162202553, 163109117, 164193992, 164838824, 174006483, 177748769, 180177283, 188899502, 198940281, 223682527, 223704702
|
||||
Target and Pathway | |||||
Target(s) | Aurora protein kinase | Target Info | Inhibitor | [3] | |
mRNA of Aurora B | Target Info | Inhibitor | [3] | ||
Aurora kinase B | Target Info | Inhibitor | [4] | ||
Aurora kinase A | Target Info | Inhibitor | [4] | ||
KEGG Pathway | Oocyte meiosishsa04114:Oocyte meiosis | ||||
Pathway Interaction Database | Aurora B signaling | ||||
Signaling by Aurora kinases | |||||
Aurora C signaling | |||||
FOXM1 transcription factor network | |||||
Aurora A signalingaurora_b_pathway:Aurora B signaling | |||||
Integrin-linked kinase signaling | |||||
PLK1 signaling events | |||||
Aurora A signaling | |||||
Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
Separation of Sister Chromatids | |||||
Resolution of Sister Chromatid Cohesion | |||||
RHO GTPases Activate ForminsR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
RHO GTPases Activate Formins | |||||
Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
Regulation of PLK1 Activity at G2/M Transition | |||||
WikiPathways | EGF/EGFR Signaling Pathway | ||||
JAK/STAT | |||||
Gastric Cancer Network 1 | |||||
Integrated Breast Cancer Pathway | |||||
APC/C-mediated degradation of cell cycle proteinsWP2757:Mitotic Metaphase and Anaphase | |||||
Mitotic Prometaphase | |||||
Regulation of Microtubule Cytoskeleton | |||||
miR-targeted genes in lymphocytes - TarBase | |||||
miR-targeted genes in epithelium - TarBase | |||||
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway | |||||
APC/C-mediated degradation of cell cycle proteins | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7937). | ||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025382) | ||||
REF 3 | J Med Chem. 2005 Apr 21;48(8):3080-4.Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. | ||||
REF 4 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.